Table 5.
FITN vs NFIT | OR | p value | 95% CI |
---|---|---|---|
Age | 1.05 | 0.093 | 0.99 to 1.12 |
Sex | 0.28* | 0.008 | 0.11 to 0.72 |
TSPAN8 | 0.37 | 0.000 | 0.26 to 0.51 |
LGALS4 | 2.16 | 0.001 | 1.38 to 3.36 |
CEACAM6 | 1.35 | 0.142 | 0.90 to 2.01 |
FITN vs LR | OR | p value | 95% CI |
Age | 1.11 | 0.000 | 1.05 to 1.18 |
Sex | 0.52* | 0.139 | 0.22 to 1.24 |
TSPAN8 | 0.39 | 0.000 | 0.28 to 0.53 |
LGALS4 | 1.47 | 0.099 | 0.93 to 2.34 |
CEACAM6 | 0.93 | 0.666 | 0.65 to 1.31 |
FITN vs HR/CRC | OR | p value | 95% CI |
Age | 1.18 | 0.000 | 1.12–1.24 |
Sex | 0.64* | 0.221 | 0.31 to 1.31 |
TSPAN8 | 0.37 | 0.000 | 0.28 to 0.49 |
LGALS4 | 0.87 | 0.502 | 0.58 to 1.30 |
CEACAM6 | 0.94 | 0.687 | 0.71 to 1.26 |
CEACAM6, carcinoembryonic antigen-related cell-adhesion molecule 6; LGALS4, lectin galactoside-binding soluble 4; TSPAN8, tetraspanin 8; OR, odds ratio; CI confidence intervals. FITN, faecal immunochemical test negative; NFIT, negative colonoscopy positive faecal immunochemical test; LR, low risk; HR/CRC, high risk - colorectal carcinoma.
*The reference group for sex is female.